Doo Young Jung
Founder & Chief Executive Officer Pinot Bio, Inc.
Founder and CEO of Pinotbio, Inc. Invented a novel proprietary Top1i payload, PBX-7016, a hydrophilic, tandem-cleavage linker system and brought them through INDs. Experienced and versatile Ph. D., pharmaceutical R&D/scientific affairs professional. Various experiences in oncology R&D, including Top1i payload ADC.
Seminars
- Employing a matched-pair strategy using inert payloads and non-binding antibodies, to systematically isolate and quantify the contributions of payload and target engagement to overall observed toxicity, providing a clear mechanistic attribution for dose-limiting adverse events
- Utilizing tissue microarrays with quantitative immunohistochemistry for target expression, to map the biodistribution of target antigens in critical normal organs,creating a preclinical risk assessment tool for on-target toxicity before candidate selection
- Developing computational toxicology models that partition free payload and intact ADC concentrations, to predict which component is driving clinical adverse events, informing linker design strategies to minimize systemic payload release
As ADC development continues to expand across increasingly diverse targets, payloads, and antibody formats,
understanding which molecular and physicochemical properties most strongly influence safety is critical to widening the
therapeutic window. This panel will explore which variables can be modulated to improve safety and how mechanistic insights
can be translated into smarter candidate selection by:
- Identifying the most critical determinants of ADC safety by examining how payload characteristics, antibody properties, conjugation parameters, and overall molecular design contribute to off-target toxicity and therapeutic window
- Exploring how payload and antibody properties can be strategically modulated by assessing the impact of payload physicochemical characteristics, Fc-mediated interactions, non-specific uptake mechanisms, and other molecular features on ADC distribution, cellular uptake, and toxicity
- Debating emerging strategies to improve ADC safety by design including Fc-silencing, alternative antibody formats, bispecific and biparatopic approaches, masked antibodies, and other engineering technologies, while considering how these approaches can translate mechanistic understanding into improved candidate selection and clinical safety
